The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus

Marianne Dieterich, Andreas Straube, Thomas Brandt, Walter Paulus, Ulrich Büttner

Abstract
The GABAergic drug baclofen and the cholinergic drug physostigmine were administered to patients with upbeat and downbeat nystagmus. Baclofen (orally, 5 mg three times daily) reduced nystagmus slow phase velocity and distressing oscillopilia by 25–75% in four out of five patients (two upbeat nystagmus; two downbeat nystagmus). Physostigmine (1 mg single intravenous injection) increased nystagmus in five additional patients with downbeat (1) or positional downbeat nystagmus (4) for a duration of 15–20 minutes. The different interactions of baclofen and physostigmine on neurotransmission subserving vertical vestibulo-ocular reflex could account for these effects. The response to baclofen appears to be a GABA-B-ergic effect with augmentation of the physiological inhibitory influence of the vestibulocerebellum on the vestibular nuclei. Similarly baclofen has an inhibitory effect on the velocity storage mechanism. Cholinergic action may cause the increment of nystagmus by physostigmine.

Upbeat and downbeat nystagmus in the primary position of gaze, with concomitant oscillopilia, reflect an imbalance of vertical vestibulo-ocular reflex tone in the pitch plane. Both are modulated by otolithic input. Alternatively, an imbalance of the vertical smooth pursuit system for downbeat nystagmus has been proposed. However, features of the syndrome such as fore-aft postural instability cannot be explained with this hypothesis.

The pathways for upward- and downward-vestibulo-ocular reflexes (VOR), from the vestibular nuclei to the oculomotor nuclei, are partially separated. The vertical VOR is under the influence of the cerebellum, mainly the vestibulo-cerebellum which projects on to the vestibular nuclei. Upbeat nystagmus may be induced by disrupting the upward VOR pathways within the brachium conjunctivum or within structures of the caudal brainstem, such as perihypoglossal nuclei and the ventral tegmental pathway, which modulate VOR. The downbeat nystagmus syndrome, as demonstrated in monkeys, is caused by lesions of either the floor of the fourth ventricle between the vestibular nuclei or the flocculus.

Little is known about neurotransmitters involved, although pathways for upward and downward VOR have been identified. Clinical evidence suggests cholinergic and gabaergic transmission. Cholinergic drugs (physostigmine) counteract a hyperactive horizontal VOR and disturbed fixation suppression of caloric nystagmus in familial ataxia and cerebellar degeneration. Anticholinergic drugs (scopolamine or trihexiphenidyl) suppress acquired pendular nystagmus and palatal myoclonus. The GABA-B-agonist baclofen effectively suppresses periodic and non-periodic alternating nystagmus.

In this report, we describe the effects of baclofen (GABA-B-agonist) and physostigmine (cholinergic drug) in 10 patients with acquired upbeat (2), downbeat (4), or positional downbeat nystagmus (4). In one patient 6, the effect of the anticholinergic drug biperiden, which was injected 10 minutes after physostigmine injection, was tested. It was found that baclofen inhibits upbeat and downbeat nystagmus in some patients and this has obvious clinical relevance. Physostigmine on the other hand, appeared to change the condition for the worse.

Patients and methods
Data for patients 1–10 are listed in table 1.

Patients 7–10 showed slight downbeat nystagmus, with Frenzel's glasses, in the upright position of the head and positional downbeat nystagmus in the head hanging position. After physostigmine application (1 mg), the increased downbeat nystagmus was recorded in the upright position with the eyes closed. There was no history of previous drug treatment in these patients.

Two healthy male subjects (aged 34 and 29 years respectively) were used as controls. Their eye movements were recorded with electro-oculography (EOG) before and after the intravenous injection of 1 mg physostigmine.

Horizontal and vertical eye position was recorded separately by DC-EOG with a resolution of 1 degree. The linearity of DC-EOG for recording vertical eye movements was ±30 degrees. The bandwidth of the recording system was 0–30 Hz. EOG measurements of vertical eye movements contaminated by lid artifacts were dismissed. Eye movements and stimuli were stored on a six channel tape recorder and printed on a thermoprinter.

During recordings, the subject sat in a
Table 1  Data for 10 patients

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Age/sex</th>
<th>CNS signs/symptoms</th>
<th>Nystagmus</th>
<th>MRI/CT/CSF/Aetiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>40 F</td>
<td>For eight months: dysarthria, dysphagia, numbness of the left trigeminal nerve, gait-ataxia falling to the right</td>
<td>Upbeat nystagmus syndrome</td>
<td>Hypertensive metastasis in the right ponto-medullary brainstem, Adeno-papillary cancer of the left hilum of the lung, probably solitary metastasis; no drugs before, no radiotherapy</td>
</tr>
<tr>
<td>2</td>
<td>65 F</td>
<td>For many years: oscillopsia and slight ataxia, hyper-reflexia at the right extremities, slight upward gaze palsy</td>
<td>Downbeat nystagmus syndrome</td>
<td>MRI, CSF: characteristic abnormalities due to a multiple sclerosis, Multiple sclerosis</td>
</tr>
<tr>
<td>3</td>
<td>79 F</td>
<td>For five years: dizziness oscillopsia, postural instability. Thirty year history of hypertension, dyslipidosis, mild anisocoria (OS &gt; OD)</td>
<td>Downbeat nystagmus syndrome</td>
<td>CT, EEG, BAEP, CSF, Doppler ultrasonography of the extracranial vessels and basilar artery—normal, Vascular (no medication besides antihypertensive drugs)</td>
</tr>
<tr>
<td>4</td>
<td>26 M</td>
<td>For two weeks: horizontal diplopia and dizziness; right interocular ophthalmoplegia. Spontaneous course: 12 weeks later oculomotor abnormalities and the hypertensive lesions in the MRI were both gone</td>
<td>Upbeat nystagmus syndrome (Baclofen was given in the acute phase for four weeks)</td>
<td>MRI: hyperintense area of the right midbrain tegmentum and the anterior cerebellar vermis, CT, EEG, evoked potentials, Doppler ultrasonography, CSF—normal, ?Most probably by an inflammatory plaque</td>
</tr>
<tr>
<td>5</td>
<td>32 M</td>
<td>For two months: double vision, postural instability, dizziness, ataxia, which occurred three weeks after enteritis. Progressive course</td>
<td>Downbeat nystagmus syndrome (progressive course)</td>
<td>CSF: lymphocytic pleocytosis of 14/3 cells, normal proteins, MRI, CT, cerebral angiography, evoked potentials, para-neoplastic screening methods—normal, ?Paraneoplastic</td>
</tr>
<tr>
<td>6</td>
<td>50 F</td>
<td>For eight months: ovarian cancer (stage 3), treated surgically and by cytostatic drugs. Since two months: acute cerebellar ataxia. Cortisone therapy without clinical improvement</td>
<td>Downbeat nystagmus syndrome</td>
<td>CT, CSF: evoked potentials—normal, Paraneoplastic cerebellar atrophy</td>
</tr>
<tr>
<td>7</td>
<td>30 F</td>
<td>For several years spastic paraparesis</td>
<td>Slight downbeat nystagmus with Frenzel’s glasses, positional downbeat nystagmus in head hanging position</td>
<td>MRI: a few small paraventricular lesions; CSF, CT, evoked potentials—normal, Multiple sclerosis</td>
</tr>
<tr>
<td>8</td>
<td>41 M</td>
<td>For 15 years: diabetes mellitus type II, hypertension; eosinophilic granuloma of the lung. For a few months: dizziness and instability of the gait</td>
<td>Slight downbeat nystagmus with Frenzel’s glasses, positional downbeat nystagmus in head hanging position</td>
<td>CT, CSF, evoked potentials, Doppler ultrasonography normal, ?</td>
</tr>
<tr>
<td>9</td>
<td>22 M</td>
<td>For a few months archineocerebellar ataxia, saccadic smooth pursuit in the horizontal and vertical plane</td>
<td>Slight downbeat nystagmus with Frenzel’s glasses, positional downbeat nystagmus in head hanging position</td>
<td>MRI, CSF: characteristic abnormalities due to a multiple sclerosis, Multiple sclerosis</td>
</tr>
<tr>
<td>10</td>
<td>31 M</td>
<td>For nine weeks: optic neuritis of the right eye</td>
<td>Slight downbeat nystagmus with Frenzel’s glasses, positional downbeat nystagmus in head hanging position</td>
<td>MRI, CSF: characteristic abnormalities due to a multiple sclerosis, Multiple sclerosis</td>
</tr>
</tbody>
</table>

**Results**

In all patients and conditions the mean slow phase velocity of the nystagmus was measured.

**Baclofen treatment 3 × 5 mg (patients 1–5)** (table 2)

Four patients (1–4) showed a suppression of 50 (25–75)% of the upbeat/downbeat nystagmus in the primary position of gaze and on lateral gaze or upward gaze (fig 1). In patient 2, the beneficial baclofen effect could be reproduced after termination of the treatment for two days (fig 2). Patient 5 showed no beneficial effect under baclofen treatment (the increase in the slow phase velocity of the downbeat nystagmus can be explained by clinical progression of the disease).

**Physostigmine and biperiden injections (patient 6)** (table 3)

The downbeat nystagmus on fixation straight ahead (90 deg/s) increased for 15–20 minutes after injection of 1 mg physostigmine (24 0 deg/s, fig 3). The gain for visual horizontal VOR suppression remained constant with 0.56 versus 0.57.

servo-controlled chair-drum system rotating about the vertical Z-axis. A servo-controlled laser projection on a half-spherical screen (at a distance of 1.5 m) provided the visual target for guided saccades. The test programme included measuring spontaneous nystagmus with the eyes closed and with the eyes open in the dark, fixation straight ahead, horizontal (up to 40°) and vertical (up to 20°) gaze. The vestibulo-ocular reflex (VOR) was tested by chair rotation in the light. For suppression of the VOR, the patient fixated on a small target light which moved together with the head. For quantitative evaluation of the suppression of the VOR (VOR-SUPP) the condition, when the patient was rotated in the light without fixating a target, was set 1 (no VOR suppression); a value of 0 was complete suppression of the horizontal VOR by visual fixation (perfect VOR suppression).

EOG recordings were performed before and on the third day of baclofen (3 × 5 mg) treatment (patients 1, 2, 3, 4, 5) as well as before and four to five minutes after intravenous injection of 1 mg physostigmine (patients 6, 7, 8, 9, 10) or 2 mg biperiden (patient 6).
The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus

Table 2  Upbeat and downbeat nystagmus in five patients before and during administration of 5 mg baclofen three times daily. Slow phase velocity in °/s

<table>
<thead>
<tr>
<th>SPV (°/s)</th>
<th>Before baclofen</th>
<th>With baclofen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>U</td>
<td>D</td>
</tr>
<tr>
<td>SN down</td>
<td>5-6</td>
<td>0</td>
</tr>
<tr>
<td>FIX 0°</td>
<td>19-21</td>
<td>5-7</td>
</tr>
<tr>
<td>40° R</td>
<td>9-15</td>
<td>5-6</td>
</tr>
<tr>
<td>10° L</td>
<td>20-24</td>
<td>10-16</td>
</tr>
<tr>
<td>VOR-SUPP</td>
<td>0-11</td>
<td>3-4</td>
</tr>
</tbody>
</table>

Biperiden injection (2 mg; anticholinergic drug), 10 minutes after physostigmine injection, diminished the enhanced downbeat nystagmus during fixation straight ahead from 24 to 10 deg/s, whereas the nystagmus with eyes closed was not significantly changed (15 deg/s versus 14 deg/s). The gain of visual horizontal VOR suppression was unchanged (0-56).

Physostigmine injection 1 mg (patients 7-10) (table 4)

All four patients with positional downbeat nystagmus were recorded with their heads in the upright position. They all showed an increased downbeat nystagmus with the eyes closed (for 15-20 minutes, four to five minutes after the intravenous injection of 1 mg physostigmine; table 4).

Controls

After physostigmine injection, the two control subjects did not show any eye movement disorder.

Discussion

This study was stimulated by earlier reports on the efficacy of baclofen for symptomatic treatment of periodic alternating nystagmus. In our study, a beneficial effect of baclofen was observed in two patients with upbeat nystagmus and two patients with downbeat nystagmus. One patient with downbeat nystagmus did not respond to baclofen. The four patients described here experienced a considerable reduction in oscillopsia amplitude as long as baclofen was given (low dose of 3 x 5 mg daily, observation time: two to four weeks). No adverse effects were reported. Five other patients with downbeat (1) or positional downbeat nystagmus (4) showed a distressing transient (15-20 minutes) increase of nystagmus velocity following intravenous injection of 1 mg physostigmine.

Both effects, reduction and augmentation of ocular oscillation, could be explained by the different interactions of baclofen and physostigmine on neurotransmission subserving vertical VOR.

Enhancement of acquired downbeat nystagmus by physostigmine, a cholinergic effect?

Cholinergic pathways are known to convey the visual input to the vestibulo-cerebellum (floculus, nodulus, ventral uvula, ventral parafloc-
Figure 3 EOG-recordings of vertical eye-movements in a patient (6) with downbeat nystagmus in paraneoplastic cerebellar syndrome. The downbeat nystagmus (SPV 9.0 deg/s, fixation straight ahead) increases both in amplitude and slow phase velocity (SPV 24.0 deg/s) for 15–20 minutes after intravenous injection of 1 mg physostigmine.

Table 4 Positional downbeat nystagmus (patients 7–10). Slow phase velocity (SPV in deg/s) of the downbeating nystagmus with eyes closed before and after a single intravenous injection of 1 mg physostigmine.

<table>
<thead>
<tr>
<th>Physostigmine 1 mg iv</th>
<th>7 (30, F)</th>
<th>8 (41, M)</th>
<th>9 (22, M)</th>
<th>10 (31, M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before SN hori</td>
<td>2.0 r</td>
<td>2.0 r</td>
<td>2.0 r</td>
<td>2.0 r</td>
</tr>
<tr>
<td></td>
<td>5.0 d</td>
<td>5.5 d</td>
<td>2.0 d</td>
<td>2.0 d</td>
</tr>
<tr>
<td>After SN hori</td>
<td>2.0 r</td>
<td>2.0 l</td>
<td>2.0 d</td>
<td>2.0 r</td>
</tr>
<tr>
<td></td>
<td>10.0 d</td>
<td>7.0 d</td>
<td>8.0 d</td>
<td>6.0 d</td>
</tr>
<tr>
<td>Before VOR-SUPP</td>
<td>0.63</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>After VOR-SUPP</td>
<td>0.54</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

SN = spontaneous nystagmus with eyes closed and head upright; hori = horizontal component of the downbeating nystagmus; vert = vertical component down; r = right; l = left; d = down; VOR-SUPP = suppression of horizontal vestibulo-ocular reflex by visual fixation.

Reduction of upbeat/downbeat nystagmus, a GABA-B-ergic-, or a anti-glutaminergic effect?

The inhibitory Purkinje cell output from the vestibulo-cerebellum uses GABA as an inhibitory transmitter. Aspartate and glutamate are excitatory transmitters of the cerebellar cortex. Baclofen is an effective drug in reducing the periodic alternating nystagmus that occurs after cerebellar or posterior fossa lesions or after nodulus and uvula ablation. It also appears likely that baclofen, a GABA-B-agonist, augments the physiological inhibitory influence of the vestibulo-cerebellum on the vestibular nuclei in our cases of upbeat and downbeat nystagmus. A GABA antagonist should therefore result in the opposite, a disinhibition with increased nystagmus. The only study in humans dealing with the influence of a GABA antagonist (picrotoxin) is related to the effect on peripheral vestibular function (distinct suppression of spontaneous nystagmus, vertigo, caloric excitability of the labyrinth). Its effect on the central pathways is less conclusive: a latent central spontaneous nystagmus became manifest, and a manifest central spontaneous nystagmus remained unchanged. In monkeys, Gavin and Blair found that picrotoxin was able to decrease the nystagmus time constant and the nystagmus asymmetry. It also antagonised diazepam in normal subjects, which may also be explained as a central vestibular tone imbalance rather than an effect on the visual pursuit system. This explanation is consistent with the findings by Sibony et al on horizontal and vertical eye movements in smoking in normal subjects. There are two possible explanations for the enhancement of downbeat nystagmus by physostigmine injection in our cases. Firstly, a directional imbalance of the vertical VOR causes downbeating nystagmus. A simultaneous increase in the up and down tone by physostigmine induces an absolutely greater tone imbalance between both directions which subsequently enhances downbeat nystagmus. In contrast, there was no pre-existing tone imbalance in the patient with hyperactive VOR described by Thurston et al. In this case therefore physostigmine could not enhance imbalance but reduced hyperactive VOR response.

Secondly, there is an inadequate visual input in the hyperactive VOR by the climbing fibre system. It is predicted that physostigmine can improve this input and reduce the VOR gain consistent with the patient described by Thurston et al. In patients with downbeat nystagmus of different origins, however, there might be different capacities to use the visual signal so that only some of the patients have an improvement of downbeat nystagmus by fixation. It can be speculated that in some cases physostigmine improves visual fixation. In other cases, there might be no effect on the slow phase of the downbeat nystagmus or a worsening of the visual fixation causing an increase in slow phase velocity.
The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus

increasing the time constant of the vestibular nystagmus. In addition to the fast build up of compensatory eye movements during optokinetic stimulation, there is another process with a slow build up of the slow phase velocity mediated by the “velocity storage mechanism” which causes a prolongation of the vestibular time constant. The velocity storage is also utilised in mediating interactions between the visual and vestibular system, the vertical and horizontal semicircular canals and between the otooliths and the semicircular canals. Cohen et al. could show an effect of baclofen on the VOR that could be modelled as an alteration in the time constant of the velocity-storage mechanism. Based on these results, it seems likely that the GABA-A agonist baclofen acts with an inhibitory control on the velocity storage.

There is a second explanation which seems less likely. Glutamate/aspartate have been proposed as excitatory neurotransmitters of the granule cells which then contact the dendrites of the Purkinje cells via excitatory parallel fibres. Baclofen antagonises excitatory transmission, possibly by presynaptically depressing the release of glutamate and aspartate. Its beneficial effect on disturbing upbeat and downbeat nystagmus might therefore be due to an anti-glutaminergic action on cerebellar cortex. This explanation is contradicted by the experimental observation in monkeys that the narcotic glutamate antagonist ketamine can elicit transient upbeat nystagmus (unpublished personal observation).

As baclofen seems to be a useful drug for treatment of periodic alternating nystagmus and upbeat and downbeat nystagmus, this might imply a common neurochemical mechanism. The manifestations of the different ocular motor disorders are then due to the site of the lesion. Some questions remain unanswered, such as, why are all of the patients with upbeat and downbeat nystagmus not responsive to baclofen therapy? Are these differential effects due to different sites of the lesion?

How can the contradictory effects of GABA-antagonists and glutamate antagonists be interpreted in the literature?

Finally, what is the long term efficiency of baclofen on upbeat and downbeat nystagmus?

Nevertheless, our results offer a new possibility for medical treatment for some patients with upbeat and downbeat nystagmus. Baclofen treatment should be tried in these patients. A prospective double blind study is essential to answer some of these questions.

This work was supported by Deutsche Forschungsgemeinschaft (SF 220) and Wilhelm-Sander-Stiftung.


The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus.

M Dieterich, A Straube, T Brandt, W Paulus and U Büttner

J Neural Neurosurg Psychiatry 1991 54: 627-632
doi: 10.1136/jnnp.54.7.627

Updated information and services can be found at:
http://jnnp.bmj.com/content/54/7/627

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/